Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
5.54
-0.21 (-3.61%)
May 9, 2025, 9:53 AM - Market open
Company Description
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.
Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
The company also develops SER 214 a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial.
In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases.
Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Serina Therapeutics, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 29, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Steven Ledger |
Contact Details
Address: 601 Genome Way, Suite 2001 Huntsville, Alabama 35806 United States | |
| Phone | 256 327 9630 |
| Website | serinatherapeutics.com |
Stock Details
| Ticker Symbol | SER |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001708599 |
| CUSIP Number | 81751A108 |
| ISIN Number | US81751A1088 |
| Employer ID | 82-1436829 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven A. Ledger | Chief Executive Officer and Director |
| Dr. Balkrishan Gill Ph.D. | Executive Chairman |
| Dr. J. Milton Harris Ph.D. | Co-Founder, Director Emeritus and Chair of Scientific Advisory Board |
| Gregory S. Curhan | Chief Financial Officer |
| Dr. Srini Tenjarla | Senior Vice President of Chemistry, Manufacturing and Controls and Formulation |
| Dr. Randall W. Moreadith M.D., Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2025 | 8-K | Current Report |
| May 8, 2025 | 10-Q | Quarterly Report |
| Apr 29, 2025 | 8-K | Current Report |
| Apr 28, 2025 | EFFECT | Notice of Effectiveness |
| Apr 28, 2025 | 424B5 | Filing |
| Apr 18, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 15, 2025 | 8-K | Current Report |
| Apr 14, 2025 | 8-K | Current Report |
| Apr 10, 2025 | EFFECT | Notice of Effectiveness |
| Apr 7, 2025 | UPLOAD | Filing |